Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.
BACKGROUND Lipid-lowering agents are known to reduce long-term mortality in patients with stable angina or multiple risk factors . However , the effects of lipid-lowering treatment on inflammatory process during and immediately after the acute phase of unstable angina remain unclear . In this study we assessed the effects of low-dose atorvastatin treatment , on inflammatory process in patients admitted for unstable angina with low cholesterol level . METHODS Forty-seven normocholesterolemic patients with unstable angina were r and omized into two groups , and received atorvastatin 10 mg/day ( n = 24 ) or no statin ( n = 23 ) for 6 weeks . Circulating levels of inteleukin 6 ( IL-6 ) , monocyte chemoattractant protein-1 ( MCP-1 ) , tumor necrosis factor alpha ( TNF-alpha ) and soluble vascular cell adhesion molecule ( sVCAM-1 ) were measured by their admission , and at the 1st and 6th week of the study . RESULTS Serum levels of MCP-1 and sVCAM-1 were significantly increased in the control group ( p < 0.05 ) while remained unaffected in the atorvastatin-treated group six weeks after admission . However , IL-6 and TNF-alpha levels were similarly decreased in both atorvastatin-treated and control groups . CONCLUSION Low-dose atorvastatin treatment modifies inflammatory process in patients with unstable angina and low cholesterol level , an effect seen at 6 weeks but not 1 week after admission
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .